Neuphoria Therapeutics Inc (NEUP) - Total Liabilities
Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) has total liabilities worth $6.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neuphoria Therapeutics Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See NEUP net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Neuphoria Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Neuphoria Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LS telcom AG
XETRA:LSX
|
Germany | €23.97 Million |
|
Cleanspace Holdings Ltd
AU:CSX
|
Australia | AU$5.62 Million |
|
Scage Future American Depositary Shares
NASDAQ:SCAG
|
USA | $27.43 Million |
|
DLSI
PA:ALDLS
|
France | €59.88 Million |
|
Solarmax Technology Inc. Common Stock
NASDAQ:SMXT
|
USA | $117.60 Million |
|
Star Paper Mills Limited
NSE:STARPAPER
|
India | Rs1.29 Billion |
|
Firebird Metals Ltd
AU:FRB
|
Australia | AU$784.06K |
|
Synergy House Berhad
KLSE:0279
|
Malaysia | RM147.39 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Neuphoria Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Neuphoria Therapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuphoria Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuphoria Therapeutics Inc (1999–2025)
The table below shows the annual total liabilities of Neuphoria Therapeutics Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $14.57 Million | +43.39% |
| 2024-06-30 | $10.16 Million | +114.21% |
| 2023-06-30 | $4.74 Million | -17.90% |
| 2022-06-30 | $5.78 Million | +15.34% |
| 2021-06-30 | $5.01 Million | -66.54% |
| 2020-06-30 | $14.97 Million | -40.58% |
| 2019-06-30 | $25.18 Million | -28.73% |
| 2018-06-30 | $35.34 Million | +5.43% |
| 2017-06-30 | $33.52 Million | -1.51% |
| 2016-06-30 | $34.04 Million | +19.40% |
| 2015-06-30 | $28.51 Million | +49.58% |
| 2014-06-30 | $19.06 Million | +71.11% |
| 2013-06-30 | $11.14 Million | +109.16% |
| 2012-06-30 | $5.32 Million | -11.19% |
| 2011-06-30 | $6.00 Million | +16.63% |
| 2010-06-30 | $5.14 Million | +5.63% |
| 2009-06-30 | $4.87 Million | -25.04% |
| 2008-06-30 | $6.49 Million | -5.76% |
| 2007-06-30 | $6.89 Million | +5.88% |
| 2006-06-30 | $6.51 Million | +33.95% |
| 2005-06-30 | $4.86 Million | +15.21% |
| 2004-06-30 | $4.22 Million | +6.87% |
| 2003-06-30 | $3.95 Million | +19.80% |
| 2002-06-30 | $3.29 Million | +904.77% |
| 2001-06-30 | $327.78K | +123.24% |
| 2000-06-30 | $146.83K | -70.98% |
| 1999-06-30 | $506.00K | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more